Effect of Aurosickle Tablet versus Standard Treatment on Quality of Life in School Going Children with Sickle Cell Disease

An Open Label Controlled Clinical Trial For Comparative Analysis Of The Effect Of Standard Drug With Tablet Aurosickle In The Management Of Sickle Cell Disease In School Going Children. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101884

Enrollment

Registered

2026-01-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D570- Hb-SS disease with crisis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of SCD Recent history of pain crisis often defined as more 2-3 episodes in the past year Current vaso-occlusive pain requiring hospitalisation or outpatient management

Exclusion criteria

Exclusion criteria: Age less than 3 years and greater than 16 years Pain associated with acute chest syndrome respiratory distress deep vein thrombosis pulmonary embolism gall bladder disease neuropathic pain etc Infections such as osteomyelitis septic arthritis pneumonia or other infections

Design outcomes

Primary

Measure	Time frame
To reduce pain crisis in sickle cell disease.Timepoint: day 7 day 14 day 21 day 28 day 35 day 42	—

Secondary

Measure	Time frame
To improve quality of life of sickle cell patients.Timepoint: day 7 day 14 day 21 day 28 day 35 day 42	—

Countries

India

Contacts

Public ContactDr Swapnil Raskar

Parul Institute Of Ayurveda Vadodara Gujarat

swapnil.raskar@paruluniversity.ac.in9726587013

Outcome results